secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2026-07-30T20:02:28+00:00
Accession:  0000914475-26-000035
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q2 revenue $959M (+39% YoY); raises INGREZZA guidance to $2.825-2.875B
--------------------------------------------------------------------------------

- GAAP EPS $1.39 vs $1.06 YoY; Non-GAAP EPS $2.85 vs $1.65 YoY.
- INGREZZA net sales $716M (+15% YoY); full-year guidance raised from $2.7-2.8B to $2.825-2.875B.
- CRENESSITY sales $184M (+247% YoY); VYKAT XR contributed $54M from May 18 acquisition close.
- Acquired Soleno Therapeutics for $53/share ($2.9B equity value) in May; added VYKAT XR for Prader-Willi syndrome.
- Entered $1.0B revolving credit facility; cash & securities $482M (down from $2.543B at year-end due to acquisition).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/0000914475-26-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/nbix-20260730.htm
  HTML page:      https://secwatch.observer/filing/0000914475-26-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer